AATD is an inherited disorder whose primary consequence is life-threatening pulmonary emphysema ... RNA-editing drug WVE-006 given in a single subcutaneous dose, although that treatment ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...